Determining the Reproductive Health of Men Post-COVID-19 Infection

Infertility, Male Clinical Trial

Official title:

Determining the Reproductive Health of Men Post-COVID-19 Infection

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04414904
• Other study ID #: 20HH5998
• Status: Withdrawn
• Start date: June 10, 2020
• Est. completion date: June 10, 2020

Study information

• Verified date: November 2020
• Source: Imperial College London
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Study rationale

1. An increasing proportion of the worldwide population is being infected with COVID-19.

2. There are ongoing and currently unanswered safety concerns about the effects of COVID-19 on reproductive health.

3. It will be immensely reassuring to rapidly report that COVID-19 has no detectable effects on male endocrine or sperm function. Conversely, if COVID-19 does impair male reproductive health, appropriate screening can be performed in couples trying to conceive, and further research can be undertaken.

4. The proposed study will be simple, rapid, and authoritative for the UK and worldwide.

Description:

Male infertility results from impaired sperm function, and account for half of all infertility. Fertility services have been reported to cost £325M annually in the UK(4) (REF). Testosterone deficiency is one of the most common hormonal problems affecting men, leading to osteoporosis, type 2 diabetes, obesity and depression(5).

Concerns have been raised about the potential effects of COVID-19 on male reproductive dysfunction (male infertility and testosterone deficiency). A recent study has suggested that COVID-19 may enter human cells by binding to receptors (special gates on cells that recognise a specific molecule) for angiotensin converting enzyme 2 (ACE2)(6) . ACE2 receptors are found at very high levels in the testes. Within the testes, ACE2 is found on developing sperm, the 'nurse cells' that help the sperm grow (Sertoli cells), and also on Leydig cells which are needed to make the male sex hormone testosterone. In summary, this evidence suggests that there is a plausible link why COVID-19 would cause male infertility and testosterone deficiency.

All fertility treatment in the UK is regulated by the Human Fertility and Embryology Authority (HFEA). The HFEA has prohibited on all non-cancer fertility treatment in the UK between April 15th and May 12th 2020 due to the COVID-19 epidemic. It is important to rapidly screen and report whether COVID-19 has any obvious effects in causing male infertility and testosterone deficiency. It must be noted that a recent study(1) reported that COVID-19 is not spread by human semen and therefore, semen processing should not risk staff to COVID-19 infection.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: June 10, 2020
• Est. primary completion date: June 10, 2020
• Gender: Male
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• Men 18-50 years of age

• Already attending hospital for another reason

• Low risk of prior COVID-19 infection(EITHER Negative positive COVID-19 PCR test result within last 4 weeks OR no history suggestive of COVID-19 illness)

• High risk of prior COVID-19 infection(EITHER Prior positive COVID-19 PCR test result OR history suggestive of COVID-19 illness)

Exclusion Criteria:

• Men with current symptoms of COVID-19 infection

• Men currently self-isolating as per UK government advice for COVID-19 infection

• Needle-phobia

• Impaired ability to provide full consent to take part in the study

• History of co-morbidity likely to affect male reproductive function e.g. undescended testes, removal of testes, testicular cancer, drugs such as corticosteroids or testosterone therapy.

Related Conditions & MeSH terms

• Infertility
• Infertility, Male
• Testosterone Deficiency

Intervention

Other:
• Exposure: Covid-19 infection
Previous history of COVID-19 infection.

Locations

Country	Name	City	State
United Kingdom	Channa Jayasena	London	Outside U.S./Canada

Sponsors (1)

Lead Sponsor	Collaborator
Imperial College London

Country where clinical trial is conducted

United Kingdom, 

References & Publications (4)

Hackett G, Kirby M, Edwards D, Jones TH, Rees J, Muneer A. UK policy statements on testosterone deficiency. Int J Clin Pract. 2017 Mar;71(3-4). doi: 10.1111/ijcp.12901. Epub 2017 Mar 20. — View Citation

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, Bi Y, Ma X, Zhan F, Wang L, Hu T, Zhou H, Hu Z, Zhou W, Zhao L, Chen J, Meng Y, Wang J, Lin Y, Yuan J, Xie Z, Ma J, Liu WJ, Wang D, Xu W, Holmes EC, Gao GF, Wu G, Chen W, Shi W, Tan W. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020 Feb 22;395(10224):565-574. doi: 10.1016/S0140-6736(20)30251-8. Epub 2020 Jan 30. — View Citation

Wang S, Zhou X, Zhang T, Wang Z. The need for urogenital tract monitoring in COVID-19. Nat Rev Urol. 2020 Jun;17(6):314-315. doi: 10.1038/s41585-020-0319-7. Review. — View Citation

Wang Z, Xu X. scRNA-seq Profiling of Human Testes Reveals the Presence of the ACE2 Receptor, A Target for SARS-CoV-2 Infection in Spermatogonia, Leydig and Sertoli Cells. Cells. 2020 Apr 9;9(4). pii: E920. doi: 10.3390/cells9040920. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Semen parameters	Sperm concentration (x10^6/ml) between case and control group.	3 visits (up to 75 days apart)
Primary	Sperm Parameters	Sperm Motility (%) between case and control group.	3 visits (up to 75 days apart)
Primary	Sperm Parameters	Sperm normal morphology (%) between case and control group.	3 visits (up to 75 days apart)
Primary	Hormones measurement	Testosterone (nmol/L) between case and control group.	3 visits (up to 75 days apart)
Primary	Hormones measurement	Follicle Stimulating Hormone(IU/L) between case and control group.	3 visits (up to 75 days apart)
Primary	Hormones measurement	Luteinising hormone(IU/L) between case and control group.	3 visits (up to 75 days apart)
Secondary	Seminal Reactive oxygen species	Compare seminal reactive oxidative species (RLU/second/10^6sperm) between case and control group.	3 visits (up to 75 days apart)
Secondary	Sperm DNA fragmentation rate	Compare Sperm DNA fragmentation rate (%) between case and control group.	3 visits (up to 75 days apart)

External Links

•   Reference 1
•   The state of the fertility sector 2017-2018